CR20250017A - Compuestos macrocíclicos para el tratamiento de cáncer - Google Patents
Compuestos macrocíclicos para el tratamiento de cáncerInfo
- Publication number
- CR20250017A CR20250017A CR20250017A CR20250017A CR20250017A CR 20250017 A CR20250017 A CR 20250017A CR 20250017 A CR20250017 A CR 20250017A CR 20250017 A CR20250017 A CR 20250017A CR 20250017 A CR20250017 A CR 20250017A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cancer
- treatment
- compounds
- macrocycle compounds
- zvfdhhx
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula (I), <img alt="" src="data:image/png;base64,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 (***)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022106792 | 2022-07-20 | ||
| CN2022128979 | 2022-11-01 | ||
| CN2023070766 | 2023-01-05 | ||
| CN2023087631 | 2023-04-11 | ||
| PCT/EP2023/069851 WO2024017859A1 (en) | 2022-07-20 | 2023-07-18 | Macrocycle compounds for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20250017A true CR20250017A (es) | 2025-03-03 |
Family
ID=87514141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20250017A CR20250017A (es) | 2022-07-20 | 2023-07-18 | Compuestos macrocíclicos para el tratamiento de cáncer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20250268894A1 (es) |
| EP (1) | EP4558507B1 (es) |
| JP (1) | JP2025525565A (es) |
| KR (1) | KR20250034953A (es) |
| CN (1) | CN119585284A (es) |
| AR (1) | AR129934A1 (es) |
| AU (1) | AU2023311244A1 (es) |
| CA (1) | CA3261063A1 (es) |
| CL (1) | CL2025000081A1 (es) |
| CO (1) | CO2025001184A2 (es) |
| CR (1) | CR20250017A (es) |
| IL (1) | IL316706A (es) |
| MA (1) | MA71551A (es) |
| MX (1) | MX2025000642A (es) |
| PE (1) | PE20250850A1 (es) |
| TW (1) | TWI860785B (es) |
| WO (1) | WO2024017859A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| KR20250085767A (ko) | 2022-09-29 | 2025-06-12 | 광조우 조요 파마테크 컴퍼니 리미티드 | 거대고리 유도체 및 이의 적용 |
| CN120813588A (zh) | 2023-02-14 | 2025-10-17 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的三环化合物 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015740A1 (en) * | 2024-07-11 | 2026-01-15 | Treeline Biosciences, Inc. | Macrocyclic ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220218852A1 (en) | 2019-04-18 | 2022-07-14 | Provincial Health Services Authority | Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy |
| AU2020377925A1 (en) * | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CA3194067A1 (en) * | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
-
2023
- 2023-07-14 AR ARP230101857A patent/AR129934A1/es unknown
- 2023-07-18 KR KR1020257001146A patent/KR20250034953A/ko active Pending
- 2023-07-18 CN CN202380054201.7A patent/CN119585284A/zh active Pending
- 2023-07-18 EP EP23748009.0A patent/EP4558507B1/en active Active
- 2023-07-18 JP JP2025502539A patent/JP2025525565A/ja active Pending
- 2023-07-18 PE PE2025000193A patent/PE20250850A1/es unknown
- 2023-07-18 IL IL316706A patent/IL316706A/en unknown
- 2023-07-18 AU AU2023311244A patent/AU2023311244A1/en active Pending
- 2023-07-18 WO PCT/EP2023/069851 patent/WO2024017859A1/en not_active Ceased
- 2023-07-18 CA CA3261063A patent/CA3261063A1/en active Pending
- 2023-07-18 CR CR20250017A patent/CR20250017A/es unknown
- 2023-07-18 MA MA71551A patent/MA71551A/fr unknown
- 2023-07-19 TW TW112126951A patent/TWI860785B/zh active
-
2025
- 2025-01-13 CL CL2025000081A patent/CL2025000081A1/es unknown
- 2025-01-16 US US19/025,165 patent/US20250268894A1/en active Pending
- 2025-01-16 MX MX2025000642A patent/MX2025000642A/es unknown
- 2025-01-31 CO CONC2025/0001184A patent/CO2025001184A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR129934A1 (es) | 2024-10-16 |
| EP4558507A1 (en) | 2025-05-28 |
| CA3261063A1 (en) | 2024-01-25 |
| CN119585284A (zh) | 2025-03-07 |
| IL316706A (en) | 2024-12-01 |
| WO2024017859A1 (en) | 2024-01-25 |
| TWI860785B (zh) | 2024-11-01 |
| PE20250850A1 (es) | 2025-03-21 |
| JP2025525565A (ja) | 2025-08-05 |
| CL2025000081A1 (es) | 2025-03-28 |
| US20250268894A1 (en) | 2025-08-28 |
| TW202413378A (zh) | 2024-04-01 |
| KR20250034953A (ko) | 2025-03-11 |
| AU2023311244A1 (en) | 2024-11-14 |
| MX2025000642A (es) | 2025-03-07 |
| EP4558507B1 (en) | 2026-04-29 |
| MA71551A (fr) | 2025-05-30 |
| CO2025001184A2 (es) | 2025-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20250017A (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| CR20240563A (es) | Inhibidores macrocíclicos de kras para el tratamiento del cáncer | |
| MA53069A1 (fr) | Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer | |
| EP3755321A4 (en) | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR THE TARGETING OF PROSTATE CANCER | |
| Bolton et al. | Effects of sulfane sulfur content in benzyl polysulfides on thiol-triggered H2S release and cell proliferation | |
| EA201171463A1 (ru) | АНТИТЕЛА ПРОТИВ EpCAM | |
| MA52486B1 (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MX2012002031A (es) | Moleculas pequeñas que contienen boro como agentes antiprotozoarios. | |
| WO2021216556A3 (en) | Oligonucleotides for msh3 modulation | |
| WO2020018503A3 (en) | Anti-il36r antibodies | |
| HRP20210263T1 (hr) | Anti- cd123 antitijela i njihovi konjugati i derivati | |
| CY1119051T1 (el) | Αντισωματα anti-c4.4a και χρησεις αυτων | |
| RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| MY162692A (en) | Boron-containing small molecules | |
| RU2014108042A (ru) | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли | |
| RU2011145038A (ru) | Несущие аматоксины мишень-связывающие молекулы для лечения рака | |
| EA202090068A1 (ru) | Соединения, влияющие на синтез пигмента и их применение для лечения бактериальных заболеваний | |
| MX2024005831A (es) | Conjugado de anticuerpo biespecifico-farmaco de camptotecina y uso farmaceutico del mismo. | |
| PE20250159A1 (es) | Conjugados de neodegradador-anticuerpo anti-cd33 | |
| KR20240151847A (ko) | 항체-약물 콘쥬게이트 | |
| EP3016983B1 (en) | A new fusion protein to target and treat acute myloid leukemia cells | |
| MX2017012759A (es) | Moléculas pequeñas que contienen boro como agentes antiprotozoarios. | |
| JP2026511031A (ja) | Ｄｌｌ３抗体－薬物コンジュゲート及びその使用 | |
| BR112024001188A2 (pt) | Moduladores de canais de potássio | |
| EP4487874A1 (en) | Antibody-drug conjugate precursor and intermediate for synthesis thereof |